REVB Revelation Biosciences, Inc.

-

Revelation Biosciences Missed Consensus Estimates

Thursday, August 6, 2026 · 12:00 AM ET

Revelation Biosciences (REVB) reported a loss of $0.87 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.83 per share. The company missed consensus estimates by 4.82%.

Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.87)
Earnings Whisper®
Consensus Estimate
($0.83)
Earnings Surprise
Earnings Growth87.6 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth